Intercell Ag

Boehringer Ingelheim International Gmbh

Valneva Austria Gmbh

Michael Buschle

Frank Mattner

Wolfgang Zauner

Walter G Schmidt

Karen Lingnau

Jörg Fritz

Eszter Nagy

Max L Birnstiel

Alena Egyed

André Habel

Karin Prinz

Ernst Wagner

Christoph Klade

Oresta Vytvytska

Peter Steinlein

Jack Melling

Tamàs Schweighoffer

Helen Kirlappos

Sandra Zinke

Alexander Otava

Jörge Fritz

Julia-Kristina Fleitmann

Jorg Fritz

Joerg Fritz

The invention relates to a vaccine which comprises at least one antigen and a peptide comprising a sequence R&#x2014;XZXZXZX&#x2014;R, whereby N is a whole number between 3 and 7, preferably 5, X is a positively charged natural and/or non-natural amino acid residue, Z is an amino acid residue selected from the group consisting of L, V, I, F and/or W, and Rand Rare selected independently one from the other from the group consisting of &#x2014;H, &#x2014;NH, &#x2014;COCH, &#x2014;COH, a peptide with up to 20 amino acid residues or a peptide reactive group or a peptide linker with or without a peptide; X&#x2014;Rmay also be an amide, ester or thioester of the C-terminal amino acid residue, as well as the use of said peptide for enhancing a patient's adaptive immune response to an antigen.

Vaccine composition comprising an antigen and a peptide having adjuvant properties

The invention refers an improved vaccine against infections with pathogens, especially viral pathogens, comprising an antigen, a peptide of the formula R&#x2014;XZSZ&#x2014;XZX&#x2014;Rand an immunostimulatory deoxynucleic acid containing deoxyinosine and/or deoxyuridine residues.

Vaccines comprising an immunostimulatory peptide and an immunostimulatory oligodeoxynucleic acid molecule

The invention relates to a vaccine which comprises at least one antigen and a peptide comprising a sequence R&#x2014;XZXZXZX&#x2014;R, whereby

The invention relates to immunogenic compositions. In certain embodiments, the invention provides pharmaceutical compositions comprising an antigen, an immunostimulating substance selected form neuroactive compounds, hormones, compounds having a growth hormone activity, and mixtures thereof, and a polycationic polymer.

Pharmaceutical composition comprising an antigen

The invention refers to an improved vaccine against infections with pathogens, especially viral pathogens, comprising an antigen, a peptide of the formula R&#x2014;XZXZ-XZX&#x2014;Rand an immunostimulatory deoxynucleic acid containing deoxyinosine and/or deoxyuridine residues.

Vaccines

Described is a vaccine which comprises at least one antigen and at least one cathelicidin derived antimicrobial peptide or a derivative thereof as well as the use of a cathelicidin derived antimicrobial peptide or a derivative thereof for the preparation of an adjuvant for enhancing the immune response to at least one antigen.

Method of vaccination comprising administering an antigen and a cathelicidin derived antimicrobial peptide

Described is a method for isolating Hepatitis C Virus peptides (HPs) which have a binding capacity to a MHC/HLA molecule or a complex comprising said HCV-peptide and said MHC/HLA molecule characterized by the following steps: &#x2014;providing a pool of HCV-peptide, said pool containing HCV-peptides which bind to said MHC/HLA molecule and HCV-peptides which do not bind to said MHC/HLA molecule, &#x2014;contacting said MHC/HLA molecule with said pool of HCV-peptides whereby a HCV-peptide which has a binding capacity to said MHC/HLA molecule binds to said MHC/HLA molecule and a complex comprising said HCV-peptide and said MHC/HLA molecule is formed, &#x2014;detecting and optionally separating said complex from the HCV-peptide which do not bind to said MHC/HLA molecule and optionally isolating and characterizing the HCV-peptide from said complex.

Method for isolating hepatitis C virus peptides

The invention relates to the use of a polycationic compound for the preparation of a medicament with retarded in vivo release.

Uses for polycationic compounds

The invention relates to a composition comprising

Antigenic composition

Pharmaceutical composition containing at least one peptide or protein (fragment) with an immunomodulatory activity together with an adjuvant. The peptide is derived from a pathogenic agent or a tumour antigen. The adjuvant is capable of increasing the binding of the peptide to the cells of the individual to be treated or of increasing the entry of the peptide into the cells and strengthening the immunomodulatory activity of the peptide. Preferred adjuvants are basic polyamino acids such as polyarginine or polylysine, optionally conjugated with a cellular ligand such as a carbohydrate group or transferrin. The composition is particularly intended for use as a vaccine, e.g. as a tumour vaccine.

Pharmaceutical composition for immunomodulation based on peptides and adjuvants

A vaccine containing one or more synthetic or highly purified natural peptides or proteins as antigen(s) as well as one or more adjuvants is present in the form of a solution or emulsion which is free from inorganic salt ions or has a low concentration of salt ions. Preferably, it contains substances capable of making the vaccine isotonic, particularly sorbitol.

Growing community of inventors

Perchtoldsdorf, Austria

Michael Buschle